Clinical trials in Poitiers – page 7

623 clinical trials in Poitiers, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Poitiers at a glance

623

clinical trials

Research sites1

Quick filters

623 trials in Poitiers

Open in trial search

Pulmonary arterial hypertension

Recruiting

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

Study comparing tadalafil with ambrisentan versus tadalafil alone in newly diagnosed patients with pulmonary arterial hypertension who have cardiovascular conditions

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ambrisentan
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Craniocerebral injury

Recruiting

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

Study of hypertonic saline solution and mannitol to improve recovery in patients with traumatic brain injury and high risk of intracranial hypertension

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Mannitol
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Colorectal cancer

Recruiting

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo

Study of ONO-4578 and nivolumab with drug combination for first-line treatment in patients with PD-L1 positive advanced colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Ono Pharmaceutical Co. Ltd.

Contact Research Centre

Gastric cancer stage IV+1

Recruiting

Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

Registered drugNo placebo

Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Levofolinate
Sponsor:Unicancer

Contact Research Centre

Endocarditis staphylococcal

Recruiting

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo

Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cefazolin Sodium
Sponsor:Centre Hospitalier Universitaire De Nantes

Contact Research Centre

Plasma cell myeloma

Recruiting

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ranibizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Sarcoma+4

Recruiting

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Zanidatamab
Sponsor:Unicancer

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Poitiers

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and various advanced cancers. Studies are evaluating novel therapeutic combinations and treatment strategies for better patient outcomes.

Advanced Gastric Cancer Treatments
Pancreatic Adenocarcinoma Therapy
Myelodysplastic Syndromes

Several trials are investigating targeted therapies and immunotherapy approaches for various cancer types.

02 Neurological Studies

Research focusing on essential tremor treatments and innovative therapeutic approaches. Clinical trials are evaluating new medications for movement disorders.

Movement Disorders
Neurological Conditions
Early Psychosis Treatment

Studies aim to improve patient quality of life through novel therapeutic interventions.

03 Transplant Medicine

Advanced research in kidney transplantation and post-transplant care, including studies on antibody-mediated rejection prevention and treatment strategies.

Organ Transplantation
Immunosuppression Protocols
Rejection Prevention

Trials focus on improving long-term outcomes for transplant recipients.

04 Critical Care Medicine

Studies evaluating postoperative care and pain management in critical care settings, including innovative approaches to patient comfort and recovery.

Pain Management
Postoperative Care
Patient Comfort Optimization

Research aims to enhance patient comfort and recovery in intensive care settings.

Back to France All countries